Bobossi‐Serengbe 2015.

Methods	Trial design: randomized trial Trial dates: June to August 2010
Participants	Number of participants: 212 hospitalized children Inclusion criteria: children between 6 and 59 months with clinical signs of severe malaria; P falciparum infection; and informed consent from parents or guardians. Exclusion criteria: children with known hypersensitivity to quinine.
Interventions	Intramuscular artemether Loading dose of 2 mg/kg on admission at 12 hour intervals... ...followed by 2 mg/kg once daily for 2 days. Intravenous quinine Loading dose 10 mg salt/kg body weight on admission... ...followed by 10 mg/kg every 4 hours for 3 days... ...then oral quinine continued until the 7th day.
Outcomes	Outcomes included in the review: Death Proportion with parasitaemia on day 3 and day 7 Adverse events Outcomes not included in the review: none
Notes	Location: Bangui Pediatric Complex, Bangui, Central African Republic Transmission: stable perennial transmission Funding: not stated
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Web‐based block randomization used.
Allocation concealment (selection bias)	Unclear risk	Not stated.
Blinding (performance bias and detection bias) Objective outcome: Death	Low risk	Not stated. However, lack of blinding is unlikely to bias an objective outcome like death.
Blinding (performance bias and detection bias) Subjective outcomes: Others	High risk	No blinding is described, and blinding would not be feasible as the route of administration is different for artemether and quinine.
Incomplete outcome data (attrition bias) All outcomes	Low risk	No losses to follow‐up reported.
Selective reporting (reporting bias)	Low risk	No evidence of selective reporting.
Other bias	Low risk	No other bias identified.